We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Neoadjuvant Breast Cancer Trials May Use pCR as Endpoint: EMA
Neoadjuvant Breast Cancer Trials May Use pCR as Endpoint: EMA
The European Medicines Agency is considering new trial designs using pathologic complete response, or pCR, as an endpoint in neoadjuvant breast cancer studies for patients with aggressive, early-stage breast cancer.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor